Adalimumab

Names

[ CAS No. ]:
331731-18-1

[ Name ]:
Adalimumab

Biological Activity

[Description]:

Adalimumab (anti-TNF-α) is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α).

[Related Catalog]:

Research Areas >> Inflammation/Immunology

[In Vitro]

Treatment of HUVECs with Adalimumab for up to 12 hours shows no adverse effect on their cell viability, even with a 10-fold higher concentration of Adalimumab (anti-TNF-α) than used in this study[2].

[In Vivo]

The elimination half-life (t1/2) of Adalimumab (anti-TNF-α) is long (~20 days)[1]. The enriched fluorescent-labelled adalimumab (anti-TNF-α) is observed mainly in major Oil red O-positive lesions documenting good tissue penetration of the drug into the atherosclerotic plaque, without background fluorescence of the vessel wall after vehicle control injection into hypercholesterolemic Ldlr-/- mice[2].

[References]

[1]. Ternant D, et al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol. 2015 Feb;79(2):286-97.

[2]. Oberoi R, et al. Targeting Tumor Necrosis Factor-α with Adalimumab: Effects on Endothelial Activation and Monocyte Adhesion. PLoS One. 2016 Jul 28;11(7):e0160145.

Chemical & Physical Properties

[ Molecular Formula ]:
C₆₄₂₈H₉₉₁₂N₁₆₉₄O₁₉₈₇S₄₆

[ Molecular Weight ]:
434.46288

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.